Catalent Sustainability Profile
Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative services, including drug formulation, clinical supply, and commercial manufacturing, which are designed to enhance product performance and patient experience. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent remains at the forefront of the industry, achieving significant milestones in drug delivery and development.
DitchCarbon Score
How does Catalent's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catalent's score of 47 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Catalent's reported carbon emissions
In 2023, Catalent, headquartered in the US, reported total carbon emissions of approximately 134,100,000 kg CO2e, comprising Scope 1 emissions of about 12,400,000 kg CO2e and Scope 2 emissions of approximately 39,600,000 kg CO2e. The company has made significant strides in its climate commitments, aiming for a 42% reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by fiscal year 2030, using fiscal year 2022 as a baseline. This target aligns with the Science Based Targets initiative (SBTi) and reflects a commitment to reducing emissions from fuel- and energy-related activities and employee commuting by 25% within the same timeframe. In 2022, Catalent achieved a 38% reduction in Scope 1 and Scope 2 emissions from its fiscal 2020 baseline, demonstrating progress towards its ambitious targets. The company also aims for 70% of its suppliers, by emissions, to have science-based targets by fiscal year 2028, further enhancing its sustainability efforts. Catalent's proactive approach to climate action underscores its commitment to reducing its environmental impact while contributing to global efforts to combat climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 61,000,000 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | 144,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | - |
How Carbon Intensive is Catalent's Industry?
How Carbon Intensive is Catalent's Location?
Catalent's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Catalent's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Catalent has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Akums Drugs and Pharmaceuticals Limited
Thermo Fisher Scientific
Frequently Asked Questions
Common questions about Catalent's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.